Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.01.2024 | Case report

Mycophenolate-mofetil/rituximab

Impaired seroconversion

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Ferri C, et al. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase. Journal of Translational Autoimmunity 7: Dec 2023. Available from: URL: https://dx.doi.org/10.1016/j.jtauto.2023.100212 Ferri C, et al. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase. Journal of Translational Autoimmunity 7: Dec 2023. Available from: URL: https://​dx.​doi.​org/​10.​1016/​j.​jtauto.​2023.​100212
Metadaten
Titel
Mycophenolate-mofetil/rituximab
Impaired seroconversion
Publikationsdatum
01.01.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-52316-0

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Immune-globulin

Case report

Sirolimus

Case report

Phenobarbital